Why Asia is the Emerging Epicenter for Global Biopharmaceutical Progress

I'm Daniel Levine, and this is the Bio Report. Asia is quickly becoming a powerhouse for biopharma innovation, changing ideas about where breakthrough science and fast, cost efficient drug development happen. A new McKinsey and Company report shows how countries like China, Japan, and India are each building their own strengths across the drug development continuum. We spoke to Fengning Zhang, a partner in McKinsey Shanghai office, about what's driving this shift, how it could make innovation more affordable, and why treating Asia as optional may mean missing the next wave of global r and d. Fangming, thanks for joining us. My pleasure. Thanks for having me. We're gonna talk about Asia as an emerging source of biopharmaceutical innovation. A new report from McKinsey and Company that analyzes that transformation and what this will mean for biopharmaceutical companies, investors, and policymakers. Let let's start with the big picture. As Asia has evolved from a a follower to a real driver of pharmaceutical innovation. It it feels like it's happened very fast. How big a shift is this, and what stands out as you look at the momentum we're seeing? So first of all, maybe let me, paint a little bit of the, the picture, so that then we can discuss, kinda what's what's, what's driving it. So for Asia, over the past five years, Asia's contribution to global innovative drug pipeline has grown from 28% to 43. So that's that's number one. And number two is if you look at, the, global growth in innovative drug pipelines, Asia has contributed 85% in 2024. On on top of that, you start to see that there are significant amount of patents. Two thirds, actually, of global patent are generated from China from Asia, and Asia suddenly increasingly is contributing to cross border licensing deals, between Asia innovators and the global players. So I think that's really a little bit of, the kind of where where Asia innovation stands today. What that means is, both in terms of the scale of the innovation that's happening as well as the pace of that progression, I think both are worth being noted by any, ecosystem players, whether you're a pharma company, biotech company, or investor. What accounts for this? Is it being driven by policy, talent, capital, or or science? What what's made this transformation possible? The way in our, research, we're actually, taking two lenses. Once we're looking at the value chain capabilities, that has been built across the key markets in the region. So that means looking at discovery, development, manufacturing, commercialization, and how, what what are the kind of the scale and relative the distinctiveness of these, capabilities in the region? And the second lens we have taken is actually looking at the underlying enablers of building that, ecosystem. Here, we actually look at it's not to your point, it's not one element that really makes a difference. It's a combination of several forces working in coherent manner that includes the government …